Publication Date:
2016-01-21
Description:
Metastatic castration-resistant prostate cancer (mCRPC) is currently a lethal disease. Although several treatment approaches, including second-generation antiandrogens or chemotherapies, have been demonstrated to improve outcomes in patients with mCRPC, each therapy increases median survival by only several months (1, 2). Thus, there is a critical need to develop novel strategies...
Print ISSN:
0027-8424
Electronic ISSN:
1091-6490
Topics:
Biology
,
Medicine
,
Natural Sciences in General
Permalink